ArticleCancer genomics & proteomics
Low Levels of Microsatellite Instability at Simple Repeated Sequences Commonly Occur in Human Hepatocellular Carcinoma.
Article in Cancer genomics & proteomics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 64 citations in OpenAlex.
- Transforming growth factor β induced as a novel secreted immune checkpoint counterinhibiting human tumor-associated T cells.Journal for immunotherapy of cancer · 2026Article
- High TRA2B expression mediated by ncRNA correlates with adverse outcomes and tumor immune infiltration in hepatocellular carcinoma.Discover oncology · 2025Article
- Existing and emerging biomarkers in hepatocellular carcinoma: relevance in staging, determination of minimal residual disease, and monitoring treatment response: a narrative review.Hepatobiliary surgery and nutrition · 2024Review
- Low incidence of microsatellite instability in gastric cancers and its association with the clinicopathological characteristics: a comparative study.Scientific reports · 2023Article
- Sequencing Systemic Therapy in Hepatocellular Carcinoma.Current treatment options in oncology · 2023Review
- Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma.BMC cancer · 2023Article
- Association of the pretreatment lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced hepatocellular carcinoma.European journal of medical research · 2023Article
- Article
- Immune Checkpoint Inhibitors Combined with Targeted Therapy: The Recent Advances and Future Potentials.Cancers · 2023Review
- Predictive Biomarkers for Immune-Checkpoint Inhibitor Treatment Response in Patients with Hepatocellular Carcinoma.International journal of molecular sciences · 2023Review
- Immunotherapy in hepatocellular carcinoma: how will it reshape treatment sequencing?Therapeutic advances in medical oncology · 2023Review
- Risk predictive model based on three immune-related gene pairs to assess prognosis and therapeutic sensitivity for hepatocellular carcinoma.World journal of surgical oncology · 2022Article
- Could We Predict the Response of Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma?Cancers · 2022Review
- Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma.Bioscience reports · 2022Review
- A Review of Emerging Biomarkers for Immune Checkpoint Inhibitors in Tumors of the Gastrointestinal Tract.Medical science monitor : international medical journal of experimental and clinical research · 2022Review
- Comprehensive analysis of immune-related gene signature based on ssGSEA algorithms in the prognosis and immune landscape of hepatocellular carcinoma.Frontiers in genetics · 2022Article
- Molecular Noninvasive Diagnosis of Hepatocellular Carcinoma Using Microsatellite Instability.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- Immunotherapy against programmed death-1/programmed death ligand 1 in hepatocellular carcinoma: Importance of molecular variations, cellular heterogeneity, and cancer stem cells.World journal of stem cells · 2021Review
- Clinical Trials of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.Journal of clinical medicine · 2021Review
- Mutation profile and its correlation with clinicopathology in Chinese hepatocellular carcinoma patients.Hepatobiliary surgery and nutrition · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimThe aim of this study was to assess the incidence of MSI in a large series of human hepatocellular carcinomas (HCC) with various etiologies. MATERIALS AND
methodsThe MSI status was determined by polymerase chain reaction (PCR) using 5 mononucleotide and 13 CAn dinucleotide repeats.
resultsNone of the 122 HCC samples displayed an MSI-High phenotype, as defined by the presence of alterations at more than 30% of the microsatellite markers analyzed. Yet, limited microsatellite instability consisting in the insertion or deletion of a few repeat motifs was detected in 32 tumor samples (26.2%), regardless of the etiology of the underlying liver disease. MSI tended to be higher in patients with cirrhosis (p=0.051), possibly reflecting an impact of the inflammatory context in this process.
conclusionBased on a large series of HCC with various etiologies, our study allowed us to definitely conclude that MSI is not a hallmark of HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.